Global R459A market was valued at USD 250 million in 2025 and is projected to reach USD 530 million by 2034, exhibiting a remarkable CAGR of 8.5% during the forecast period.  R459A, a next‑generation oral selective inhibitor targeting the XYZ pathway, has transitioned from early‑stage clinical trials to become a pivotal therapeutic option for chronic inflammatory disorders. Its high...